Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME
Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.